Updated:
Smith & Nephew Plc
Smith & Nephew was founded in Hull, England in 1856 by Thomas Smith, a pharmacist who initially sold wound dressings.
Smith & Nephew Plc
Smith & Nephew was founded in Hull, England in 1856 by Thomas Smith, a pharmacist who initially sold wound dressings. The company has evolved into a multinational medical technology business, listed on the London Stock Exchange and a constituent of the FTSE 100. Deepak Nath, a former Siemens Healthineers executive, became CEO in 2022. The firm's strategy focuses on three core segments: orthopedics (hip and knee replacements, robotic-assisted surgery via its NAVIO system), sports medicine and ENT (arthroscopy, joint repair, and sinus dilation), and advanced wound management (negative pressure therapy, antimicrobial dressings). Smith & Nephew generates roughly $5 billion in annual revenue. The company has a global manufacturing and R&D footprint spanning the US, UK, Ireland, Germany, and China. Known portfolio products include the CORI surgical robot and PICO single-use negative pressure wound therapy. Smith & Nephew employs approximately 18,000 people across more than 100 countries. The company maintains a dual-listed corporate structure but is headquartered in London with major operational hubs in Durham, North Carolina and Park City, Utah. The firm's philanthropic arm, the Smith & Nephew Foundation, supports healthcare education and research. 2024: Deepak Nath outlined a three-year strategic plan to improve margins and accelerate growth in robotics and emerging markets. The structural differentiator is Smith & Nephew's unique hybrid position as both a historic wound-care pioneer and a modern robotic-surgery contender, straddling legacy consumables and high-tech capital equipment. This dual mandate requires the company to manage contrasting R&D cycles and regulatory pathways, a balancing act few pure-play medtech firms face.
General information
Firm type
other
Year founded
1856
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, England, United Kingdom
Additional offices
Durham, North Carolina, United States · Park City, Utah, United States
Principals
Deepak Nath
Chief Executive Officer
John Rogers
Chairman
Sector focus
Frequently asked questions
Who runs Smith & Nephew Plc?
Deepak Nath has been Chief Executive Officer since 2022, having joined from Siemens Healthineers where he ran the Diagnostics division. John Rogers serves as non-executive Chairman (per public record).
What are Smith & Nephew's main business segments?
The firm operates through three segments: Orthopaedics (hip/knee replacements and robotics), Sports Medicine & ENT (arthroscopy and sinus surgery), and Advanced Wound Management (dressings and negative pressure therapy). Together they generated approximately $5 billion in 2024 revenue (per the firm's annual report).
Does Smith & Nephew have a focus on robotics?
Yes. The firm's NAVIO and CORI surgical robotics platforms compete in the robotic-assisted orthopedic surgery market, performing partial and total knee replacements. This is a key growth area alongside emerging market expansion (per the firm's 2024 strategic plan).
Is Smith & Nephew a family office?
No. Smith & Nephew Plc is a publicly traded medical technology company listed on the London Stock Exchange. It is not a family office, but is included in this database due to its family-office-aligned legacy structure and foundation.
How is Smith & Nephew's wealth origin connected to its founding?
The company was founded by Thomas Smith, a pharmacist who created the first sterile wound dressings. The original family wealth came from the success of that early medical-supply business. However, Smith & Nephew is now a widely held public company with no controlling family stake.
What philanthropic structures are associated with Smith & Nephew?
The Smith & Nephew Foundation is the company's charitable arm, supporting healthcare education, research, and community health programs. It is a registered charity in the UK, separate from the corporate operating structure.
Which markets does Smith & Nephew consider its strongest growth areas?
The firm targets growth in robotic-assisted surgery, emerging markets (especially China and India), and advanced wound bioactives. The 2024 strategic plan highlighted margin improvement and a portfolio shift toward higher-growth segments (per the firm's communications).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: